Compare SUIG & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUIG | STXS |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 139.3M |
| IPO Year | 2022 | 2004 |
| Metric | SUIG | STXS |
|---|---|---|
| Price | $1.28 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.70 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 936.5K | 482.6K |
| Earning Date | 11-11-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | $3,898,631.00 | ★ $29,346,617.00 |
| Revenue This Year | N/A | $6.04 |
| Revenue Next Year | $120.04 | $33.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.79 | $1.05 |
| 52 Week High | $3.49 | $3.19 |
| Indicator | SUIG | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 24.62 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.29 | $1.98 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 1.85 | 5.00 |
Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.